CN112569263B

CN112569263B - Composite probiotics freeze-dried powder

Info

Publication number: CN112569263B
Application number: CN202011618295.0A
Authority: CN
Inventors: 张育文
Original assignee: Hubei Qiangfei Biotechnology Co ltd
Current assignee: Hubei Qiangfei Biotechnology Co ltd
Priority date: 2020-12-30
Filing date: 2020-12-30
Publication date: 2023-05-02
Anticipated expiration: 2040-12-30
Also published as: CN112569263A

Abstract

The application belongs to the technical field of probiotic products, and particularly relates to composite probiotic freeze-dried powder. Comprises the following components in parts by mass: 45-60% of complex carbohydrate, 4-6% of bifidobacterium infantis freeze-dried powder, 3-4% of bifidobacterium lactis freeze-dried powder, 2-4% of bifidobacterium adolescentis freeze-dried powder, 3-5% of lactobacillus rhamnosus freeze-dried powder, 2-4% of lactobacillus casei freeze-dried powder, 3-5% of bifidobacterium longum freeze-dried powder, 2-4% of lactobacillus reuteri freeze-dried powder, 1-3% of bifidobacterium animalis and 15-20% of dairy additive. Based on the traditional production and preparation method, the compound probiotic freeze-dried powder is scientifically combined with a plurality of strains, so that the auxiliary treatment effect of probiotics on hyperbilirubinemia is improved, the treatment period of hyperbilirubinemia is shortened, the infant physique is improved, the cure rate is further improved, and the medical time and the medical cost are reduced.

Description

Composite probiotics freeze-dried powder

Technical Field

The application belongs to the technical field of probiotic products, and particularly relates to composite probiotic freeze-dried powder.

Background

Hyperbilirubinemia (NHB) is a disease that has a very high incidence in infants and young children, and is generally treated effectively by rational phototherapy and careful drug therapy for mild patients. However, in the actual diagnosis and treatment process, for many areas where economy and medical technology are not developed, such therapies are not effectively applied, and because the symptoms of yellow staining and poor appetite of spirit and the like at the disease manifestation are not very intuitive and attractive for the ordinary people, the symptoms are ignored by many parents, especially aged and ideological parents and ancestors, and in fact hyperbilirubinemia not only can lead to poor mental state in a short period of an infant, but also can lead to bilirubin multi-organ damage for serious patients if the patients cannot be treated in time, and the immunity of the infant is reduced and even the central nervous is seriously damaged. Due to the limitations of environment and economic conditions, many parents adhere to the adoption of methods of self-arrangement sunlight irradiation and the like to cope with the diseases, scientific treatment plans and capabilities cannot be obtained in a home environment, the actual recovery effect and speed cannot be expected, along with the continuous appearance of probiotic products, people begin to pay attention to and research the treatment effect of oral probiotics on hyperbilirubinemia, and numerous research results are published, research objects of the probiotics mainly focus on the probiotics which are products approved and used in China at present, but the main purpose of the probiotics is to assist infant intestinal tract regulation and improve the immunity of the infants, and objectively say, the functions actually have indirect effects on improving the hyperbilirubinemia, and are worth commercializing probiotic products which can really directly and effectively improve the treatment and recovery efficiency of the diseases.

Disclosure of Invention

The purpose of the application is to provide the compound probiotic freeze-dried powder which can obviously improve the recovery and treatment effect of hyperbilirubinemia, has no side effect, is suitable for infants, and is safe to use and has no side effect.

In order to achieve the above purpose, the following technical scheme is adopted in the application.

A composite probiotic freeze-dried powder comprises the following components in parts by mass: 45-60% of complex carbohydrate, 4-6% of bifidobacterium infantis freeze-dried powder, 3-4% of bifidobacterium lactis freeze-dried powder, 2-4% of bifidobacterium adolescentis freeze-dried powder, 3-5% of lactobacillus rhamnosus freeze-dried powder, 2-4% of lactobacillus casei freeze-dried powder, 3-5% of bifidobacterium longum freeze-dried powder, 2-4% of lactobacillus reuteri freeze-dried powder, 1-3% of bifidobacterium animalis and 15-20% of dairy additive.

Further materializing the composite probiotic freeze-dried powder, wherein the specific components are as follows: the dairy product additive comprises 2-4% of bovine coloctrum freeze-dried powder, 8-12% of whole milk powder and 2-4% of vegetable fat powder.

Further materializing the composite probiotics freeze-dried powder, wherein the composite sugar comprises 20-25% of stachyose, 4-8% of isomaltooligosaccharide, 12-20% of fructooligosaccharide, 3-5% of galactooligosaccharide, 4-8% of xylooligosaccharide and 2-4% of soybean oligosaccharide.

Further materializing the composite probiotic freeze-dried powder, wherein the specific components of the composite sugar are as follows: 25% of stachyose, 4% of isomaltooligosaccharide, 15% of fructooligosaccharide, 4% of galactooligosaccharide, 5% of xylooligosaccharide and 4% of soybean oligosaccharide.

Further materializing the composite probiotic freeze-dried powder, wherein the specific components are as follows: bifidobacterium infantis freeze-dried powder BI455%, bifidobacterium lactis freeze-dried powder BLa803%, bifidobacterium adolescentis freeze-dried powder BAC303%, lactobacillus rhamnosus freeze-dried powder LRa054%, lactobacillus casei freeze-dried powder LC893%, bifidobacterium longum freeze-dried powder BL214%, lactobacillus reuteri freeze-dried powder LR083%, bifidobacterium animalis Bb-122% bovine colostrum freeze-dried powder 3%, whole milk powder 10% and vegetable fat powder 3%.

Further materializing the composite probiotic freeze-dried powder, wherein the model of the bifidobacterium infantis is BI45, the model of the bifidobacterium adolescentis is BAC30, the model of the lactobacillus rhamnosus is LRa05, the model of the lactobacillus casei is LC89, the model of the bifidobacterium longum is BL21, the model of the lactobacillus reuteri is LR08 and the model of the bifidobacterium animalis is Bb-12.

The beneficial effects are that:

based on the traditional production and preparation method, the compound probiotic freeze-dried powder is scientifically combined with a plurality of strains, so that the auxiliary treatment effect of probiotics on hyperbilirubinemia is improved, the treatment period of hyperbilirubinemia is shortened, the infant physique is improved, the cure rate is further improved, and the medical time and the medical cost are reduced.

Drawings

Figure 1 is a graph of average infant bilirubin levels over the treatment period of each group of examples.

Detailed Description

The present application is described in detail below with reference to specific examples.

To better illustrate the features of the present application and its effects, a control analysis was performed as follows with a preferred example formulation of the present application (example one), a formulation based on the deletion of components of the present application (example two), an existing certain approved complex probiotic formulation (example three), and a control group without intervention (example four).

Example 1

A preferred formulation of the present application comprises: 25% of stachyose, 4% of isomaltooligosaccharide, 15% of fructooligosaccharide, 4% of galactooligosaccharide, 5% of xylooligosaccharide, 4% of soybean oligosaccharide, 455% of bifidobacterium infantis freeze-dried powder BI, 803% of bifidobacterium lactis freeze-dried powder BLa, 303% of bifidobacterium adolescentis freeze-dried powder BAC, 054% of lactobacillus rhamnosus freeze-dried powder LRa, 893% of lactobacillus casei freeze-dried powder LC, 214% of bifidobacterium longum freeze-dried powder BL, 083% of lactobacillus reuteri freeze-dried powder LR, 3% of bifidobacterium animalis Bb-122% of bovine colostrum freeze-dried powder, 10% of whole milk powder and 3% of vegetable fat powder;

example two

A formulation for component deletion based on the present application, comprising: stachyose 25%, isomaltooligosaccharide 4%, fructooligosaccharide 15%, galactooligosaccharide 4%, xylooligosaccharide 5%, soybean oligosaccharide 4%, bifidobacterium infantis lyophilized powder BI455%, bifidobacterium lactis lyophilized powder BLa801% (decrease), bifidobacterium adolescentis lyophilized powder BAC304% (increase), lactobacillus rhamnosus lyophilized powder LRa055% (increase), lactobacillus casei lyophilized powder LC891% (decrease), bifidobacterium longum lyophilized powder BL216% (increase), lactobacillus reuteri lyophilized powder LR083%, bifidobacterium animalis Bb-122% bovine coloctrum lyophilized powder 3%, whole milk powder 10%, and non-dairy creamer 3%;

example III

The existing compound probiotic preparation belongs to a clostridium butyricum bifidobacterium viable bacteria mixed preparation, and the specific formula is unknown;

example four without intervention (control group);

the first, second and third embodiments are tested by drug toxicity, the test dosage is within the safety range of no toxicity and side effects, in particular, for the safety and treatment urgency, the test scheme does not relate to the treatment of severe infant patients, so the test objects are all determined infant cases with mild and moderate hyperbilirubinemia, in order to ensure that all objects are sufficiently treated, the test is matched with a blue light therapeutic instrument (GLQ-3L) for treatment (the average treatment time of patients is 5 h-7/d and the average treatment time of moderate is 7-9 h/d), and the explanation is carried out according to the recovery speed and the effect of corresponding infant patients, in the treatment process, basic nutrition supplement means for hyperbilirubinemia in the conventional treatment means are adopted, as the patients need long-time Wen Xiangguang oxygen treatment (according to the relevant treatment standard and experience, the average treatment time is 2 weeks), in order to ensure the treatment effect and prevent the influence of external factors, non-breast milk is adopted in the treatment stage; in the embodiment of the application, all treatment objects are obstetrical infants in the national hospitals such as the public third class first in certain county, the birth date of the infants is 2018.7-2020.10, the relatively constant temperature and humidity environment is kept in an obstetric room and an incubator in the production and treatment process, and the age standard of a parturient in the file is 20-30 in order to avoid the physiological problems of the infants caused by high-risk pregnancy by specific reference to the classification of hospital environment and the air hygiene standard; no abnormality or various symptoms during pregnancy, and voluntary participation.

The index used for statistics and analysis, namely the characterization index of the treatment effect, is the bilirubin level of the infant, and the serum total bilirubin level during the treatment period of the infant is taken as a benchmark; the following specific test cases:

table 1 average infant bilirubin level changes (μmol/L) during treatment of each group of examples

As shown in the figure 1, the average trend of the test results shows that compared with the treatment conditions of the first, second, third and fourth embodiments, compared with the control group (the fourth embodiment) without the probiotic preparation, the first, second and third embodiments adopting the probiotic composite preparation obviously improve the reduction speed and the reduction value of the bilirubin level of the infant and the infant in the whole treatment process, and prove that the application and the existing probiotic preparation are beneficial to the treatment of hyperbilirubinemia;

analysis shows that the treated subjects using the related probiotic preparation have more regular excretion of infants and bilirubin levels in feces higher than those of subjects without probiotics, and further analysis shows that bifidobacteria and clostridium glomeratum in the probiotic preparation have positive effects on ensuring colony balance advocated by infants, promoting intestinal development and digestion of infants, and have no uncomfortable condition in the treatment process, thus being suitable for the treatment of hyperbilirubinemia.

The treatment conditions of the first, second and third embodiments can be known, based on the basic formula of the compound probiotic freeze-dried powder, the treatment effect of the compound probiotic freeze-dried powder is obviously better than that of the existing clostridium butyricum bifidobacterium live bacteria mixed preparation product in the first week (0-8 day) period of treatment, namely the treatment effect of hyperbilirubinemia can be effectively improved in a shorter time, the bilirubin level of the compound probiotic freeze-dried powder is close to the normal level in the first and second embodiments of the basic formula of the application, the corresponding index can be further reduced after the compound probiotic freeze-dried powder is continuously taken in the 6-10 weeks of treatment, and the corresponding treatment period of the existing clostridium butyricum live bacteria mixed preparation product is longer, namely the average treatment period of the normal level is 10-12 days.

According to the first and second comparison examples, the preferred solution and the deleted formula solution based on the application have better bilirubin reducing effect in the early treatment period, but the infant indexes can reach the normal value, but the final indexes are different relatively, the treatment effect of the preferred solution in each stage is better than that of the deleted solution, and the effectiveness of the preferred solution of the application is proved.

Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present application, and not for limiting the scope of protection of the present application, and although the present application has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made to the technical solutions of the present application without departing from the spirit and scope of the technical solutions of the present application.

Claims

1. The composite probiotics freeze-dried powder is characterized by comprising the following components in percentage by mass: stachyose 25%, isomaltooligosaccharide 4%, fructooligosaccharide 15%, galactooligosaccharide 4%, xylooligosaccharide 5%, soybean oligosaccharide 4%, bifidobacterium infantis lyophilized powder BI455%, bifidobacterium lactis lyophilized powder BLa803%, bifidobacterium adolescentis lyophilized powder BAC303%, lactobacillus rhamnosus lyophilized powder LRa054%, lactobacillus casei lyophilized powder LC893%, bifidobacterium longum lyophilized powder BL214%, lactobacillus reuteri lyophilized powder LR083%, bifidobacterium animalis Bb-12%, bovine colostrum lyophilized powder 3%, whole milk powder 10% and vegetable fat powder 3%.